Zogenix to advance regulatory plans on second Phase III win

Zogenix Inc. (NASDAQ:ZGNX) reported top-line data showing ZX008 as an adjunctive therapy to stiripentol regimen met the primary endpoint in its second Phase III trial, Study 1504, to

Read the full 280 word article

How to gain access

Continue reading with a
two-week free trial.